Irish Journal of Psychological Medicine,
Год журнала:
2024,
Номер
unknown, С. 1 - 9
Опубликована: Ноя. 7, 2024
Abstract
Objectives:
Understanding
variations
in
knowledge
and
attitudes
of
psychiatrists
to
psilocybin
therapy
is
important
for
the
collective
discourse
about
potential
impact
on
clinical
practice
public
health
Ireland.
Methods:
A
28-item
questionnaire
was
designed
based
previous
studies
distributed
Ireland
via
online
mailing
lists
at
in-person
academic
events.
Results:
151
completed
(73.3%
were
under
40
years
age,
76.0%
trainees,
49.0%
female).
In
total
sample,
81.5%
agreed
that
shows
promise
treatment
psychiatric
disorders
86.8%
supported
funding
research,
would
be
willing
refer
a
patient
if
it
licensed
indicated,
78.1%
consider
themselves,
indicated.
Conversely,
6.6%
unsafe
even
medical
supervision,
21.9%
thought
potentially
addictive.
15.9%
sample
reported
least
one
concern
including,
lack
robust
evidence,
long-term
effectiveness,
superiority
current
interventions,
harmful
effects,
cost
accessibility,
impartiality.
Less
than
half
respondents
felt
knowledgeable
(40.0%)
9.9%
adequately
prepared
participate
therapy.
Consultant
trended
towards
less
optimism
role
bipolar
depression
emotionally
unstable
personality
disorder
compared
trainee
psychiatrists.
Conclusion:
Overall
held
positive
However,
there
evident.
Addressing
gap
aligning
with
best
available
evidence
will
key
psychedelic
prevail
setting.
Frontiers in Neuroscience,
Год журнала:
2024,
Номер
18
Опубликована: Июль 10, 2024
Alzheimer’s
disease
(AD)
stands
as
a
formidable
neurodegenerative
ailment
and
prominent
contributor
to
dementia.
The
scarcity
of
available
therapies
for
AD
accentuates
the
exigency
innovative
treatment
modalities.
Psilocybin,
psychoactive
alkaloid
intrinsic
hallucinogenic
mushrooms,
has
garnered
attention
within
neuropsychiatric
realm
due
its
established
safety
efficacy
in
treating
depression.
Nonetheless,
potential
therapeutic
avenue
remains
largely
uncharted.
This
comprehensive
review
endeavors
encapsulate
pharmacological
effects
psilocybin
while
elucidating
existing
evidence
concerning
mechanisms
contributing
positive
impact
on
AD.
Specifically,
active
metabolite
psilocybin,
psilocin,
elicits
through
modulation
5-hydroxytryptamine
2A
receptor
(5-HT2A
receptor).
causes
heightened
neural
plasticity,
diminished
inflammation,
improvements
cognitive
functions
such
creativity,
flexibility,
emotional
facial
recognition.
Noteworthy
is
psilocybin’s
promising
role
mitigating
anxiety
depression
symptoms
patients.
Acknowledging
attendant
adverse
reactions,
we
proffer
strategies
aimed
at
tempering
or
effects.
Moreover,
broach
ethical
legal
dimensions
inherent
exploration
treatment.
By
traversing
these
avenues,
We
propose
nuanced
management
disease.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Год журнала:
2025,
Номер
unknown, С. 111243 - 111243
Опубликована: Янв. 1, 2025
Chronic
stress
exerts
profound
effects
on
mental
health,
contributing
to
disorders
such
as
depression,
anxiety,
and
cognitive
impairment.
This
study
examines
the
potential
of
psilocybin
alleviate
behavioral
despair
deficits
in
a
rodent
model
chronic
stress,
focusing
interplay
between
Hypothalamic-Pituitary-Adrenal
(HPA)
axis
Endocannabinoid
System
(ECS).
Twenty-two
male
Wistar
rats
were
divided
into
control
groups.
Animals
within
group
exposed
predator
odor
social
instability
induce
either
sham
treated,
or
given
psilocybin.
Behavioral
assessments
conducted
using
Open
Field
Test,
Sucrose
Preference
Novel
Object
Recognition,
Elevated
Plus
Maze,
Forced
Swimming
Test
evaluate
locomotion,
anhedonia,
memory,
despair,
respectively.
Blood
brain
samples
analyzed
for
biochemical
markers.
Results
indicated
that
significantly
reduced
stress-induced
impairments,
likely
through
ECS-mediated
downregulation
HPA
axis.
These
findings
suggest
early
intervention
with
has
sustained
beneficial
stress-related
disturbances,
underscoring
its
novel
therapeutic
approach
health
disorders.
Journal of Psychopharmacology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 28, 2025
Background:
Psilocybin,
a
serotonin
2A
receptor
agonist
with
psychedelic
properties,
shows
promise
as
novel
treatment
for
alcohol
use
disorder
(AUD).
While
current
studies
involve
two
dosing
sessions,
the
effects
of
single
dose
have
not
been
investigated.
Aims:
To
investigate
pharmacokinetics,
feasibility,
safety
and
efficacy
single-dose
psilocybin
therapy
in
AUD.
Methods:
This
open-label,
single-group
study
investigated
10
treatment-seeking
adults
(8
men
2
women;
median
age
44
years)
severe
The
involved
preparation
high-dose
session
(25
mg)
integration
sessions.
Pharmacokinetics
were
determined
by
noncompartmental
analysis,
changes
consumption,
craving
self-efficacy,
assessed
using
linear
mixed
model.
Results:
Notable
between-participant
pharmacokinetic
variations
observed,
peak
plasma
psilocin
concentrations
ranging
from
14
to
59
µg/L.
Alcohol
consumption
significantly
decreased
over
12
weeks
following
administration.
Heavy
drinking
days
reduced
37.5
percentage
points
(95%
CI:
−61.1
−13.9,
p
=
0.005),
drinks
per
day
3.4
−6.5
−0.3,
0.03).
was
corroborated
reports
rapid
sustained
reductions
increases
self-efficacy.
Conclusions:
Despite
variations,
25
mg
safe
effective
reducing
AUD
patients.
Larger
randomised,
placebo-controlled,
trials
are
warranted.
Clinical
trial
registration:
https://clinicaltrials.gov/study/NCT04718792
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Год журнала:
2025,
Номер
unknown, С. 111361 - 111361
Опубликована: Апрель 1, 2025
Studies
of
psychedelic
use
in
naturalistic
and
clinical
settings
have
suggested
safety
mental
health
benefits
for
adults
with
histories
childhood
maltreatment.
Acute
psychological
mechanisms
that
predict
therapeutic
this
population,
however,
yet
to
be
determined.
Two
common
group
-
organized
ceremonies
raves
or
other
electronic
dance
music
events
might
facilitate
effects
because
the
unique
psychosocial
environments
they
comprise.
This
prospective,
longitudinal
study
sought
investigate
2
primary
questions:
first,
whether
maltreatment
planning
drugs
intent
at
would
see
enduring
after
their
experiences;
second,
subjective
dimensions
acute
experience
associated
lasting
benefits.
Eighty-five
participants
completed
self-report
measures
month
before,
within
days
after,
approximately
months
a
planned
ceremony
rave
assessing
history;
trauma
symptoms,
internalized
(trait)
shame,
connectedness
baseline
follow-up;
various
experience.
Mean
scores
posttraumatic
stress
disorder
(PTSD)
complex
PTSD
trait
social
connectedness,
general
significantly
improved
from
2-month
follow-up
(ds
=
0.73-1.12).
Longitudinal
changes
outcomes
correlated
These
findings
implications
regarding
both
potential
benefit
among
as
well
action
psychedelics.
Studies
of
psychedelic
use
in
naturalistic
and
clinical
settings
have
suggested
safety
mental
health
benefits
for
adults
with
histories
childhood
maltreatment.
Acute
psychological
mechanisms
that
predict
therapeutic
this
population,
however,
yet
to
be
determined.
Two
common
group
–
organized
ceremonies
raves
or
other
electronic
dance
music
events
might
facilitate
effects
because
the
unique
psychosocial
environments
they
comprise.
This
prospective,
longitudinal
study
sought
investigate
2
primary
questions:
first,
whether
maltreatment
planning
drugs
intent
at
would
see
enduring
after
their
experiences;
second,
subjective
dimensions
acute
experience
associated
post-acute
benefits.
Eighty-five
participants
completed
self-report
measures
month
before,
within
days
after,
approximately
months
a
planned
ceremony
rave
assessing
history;
trauma
symptoms,
internalized
(trait)
shame,
connectedness
baseline
follow-up;
various
experience.
Mean
scores
posttraumatic
stress
disorder
(PTSD)
complex
PTSD
trait
social
connectedness,
general
significantly
improved
from
2-month
follow-up
(d
=
0.73-1.12).
Longitudinal
changes
outcomes
correlated
These
findings
implications
regarding
both
potential
benefit
among
as
well
action
psychedelics.
